Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Efavirenz

DRUG

Adefovir dipivoxil

Trial Locations (5)

23666

Hampton Roads Med Specialists, Hampton

30308

AIDS Research Consortium of Atlanta, Atlanta

80262

Univ of Colorado / Health Science Ctr, Denver

90211

Pacific Oaks Med Group, Beverly Hills

02908

Brown Univ School of Medicine, Providence

Sponsors
All Listed Sponsors
collaborator

Glaxo Wellcome

INDUSTRY

collaborator

Dupont Applied Biosciences

INDUSTRY

lead

Gilead Sciences

INDUSTRY

NCT00002419 - Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment | Biotech Hunter | Biotech Hunter